SLFN11 and prostate carcinoma: By performing transcriptomic and single-cell analyses, we found that gemcitabine treatment in prostate cancer cells induced the expression of immune-related pathways in SLFN11-proficient cancer cells, which is in line with recent findings made with other compounds inducing replication stress (11).